Comparative study of sitagliptin with pioglitazone in Japanese type 2 diabetic patients: The COMPASS randomized controlled trial

Diabetes, Obesity and Metabolism

Volumn 15, Issue 5, 2013, Pages 455-462

  Takihata, M ^a   Nakamura, A ^a   Tajima, K ^a   Inazumi, T ^a   Komatsu, Y ^a   Tamura, H ^b   Yamazaki, S ^c   Kondo, Y ^d   Yamada, M ^e   Kimura, M ^a   Terauchi, Y ^a  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

^b Yokohama Minami Kyosai Hospital   (Japan)

^c Fujisawa City Hospital   (Japan)

^d CHIGASAKI MUNICIPAL HOSPITAL   (Japan)

^e Yokohama Sakae Kyosai Hospital   (Japan)

Author keywords

DPP IV inhibitor; Randomized trial; Type 2 diabetes

Indexed keywords

ALANINE AMINOTRANSFERASE; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ASPARTATE AMINOTRANSFERASE; CREATININE; GAMMA GLUTAMYLTRANSFERASE; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; PIOGLITAZONE; SITAGLIPTIN; SULFONYLUREA; TRIACYLGLYCEROL;

ADULT; ARTICLE; BLOOD SAMPLING; BODY MASS; BODY WEIGHT; COMPARATIVE STUDY; CONTROLLED STUDY; DIABETIC PATIENT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; FEMALE; FRACTURE; GASTROINTESTINAL SYMPTOM; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN RESISTANCE; INTENTION TO TREAT ANALYSIS; JAPANESE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; RANDOMIZED CONTROLLED TRIAL; RASH; UREA NITROGEN BLOOD LEVEL; URINALYSIS;

ADULT; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; JAPAN; MALE; METFORMIN; MIDDLE AGED; PYRAZINES; SULFONYLUREA COMPOUNDS; THIAZOLIDINEDIONES; TREATMENT OUTCOME; TRIAZOLES;

EID: 84876315358     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12055     Document Type: Article

References (38)

1. Inzucchi SE, Bergenstal RM, Buse JΒL. Management of hyperglycemia in type 2 diabetes: A patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012; 35: 1364-1379.
2. UK prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
3. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-865.
4. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW. 10-Year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359: 1577-1589.
5. Gross JL, Kramer CK, Leitao CB et al. Effect of antihyperglycemic agents added to metformin and a sulfonylurea on glycemic control and weight gain in type 2 diabetes: a network meta-analysis. Ann Intern Med 2011; 154: 672-679.
6. Phung OJ, Scholle JM, Talwar M, Coleman CI. Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes. JAMA 2010; 303: 1410-1418.
7. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 2007; 98: 1180-1188.
8. Dormandy JA, Charbonnel B, Eckland DJA et al. Secondary prevention of macrovascular events in Patients with type 2 diabetes: a randomized trial of pioglitazone. The PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events). Lancet 2005; 366: 1279-1289.
9. Patil HR, Al Badarin FJ, Shami HA et al. Meta-analysis of effect of dipeptidyl peptidase-4 inhibitors on cardiovascular risk in Type 2 diabetes mellitus. Am J Cardiol 2012; 110: 826-833.
10. The Diabetes Control and Complication Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complication in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-986.
11. Stratton IM, Adler AI, Neil HAW et al. Epidemiological association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35). BMJ 2000; 321: 405-412.
12. The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560-2572.
13. Kelly TN, Bazzano L, Fonseca VA, Theti TK, Reynolds K, He J. Systematic review: glucose control and cardiovascular disease in type 2 diabetes. Ann Intern Med 2009; 151: 394-403.
14. Currie CJ, Peters JR, Tynan A et al. Survival as a function of HbA(1c) in people with type 2 diabetes: a retrospective cohort study. Lancet 2010; 375: 481-489.
15. Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, Byington RP et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358: 2545-2559.
16. Duckworth W, Abraira C, Moritz T et al., VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009; 360: 129-139.
17. Kawamori R, Kadowaki T, Onji M, Seino Y, Akanuma Y. Hepatic safety profile and glycemic control of pioglitazone in more than 20, 000 patients with type 2 diabetes mellitus: postmarketing surveillance study in Japan. Diabetes Res Clin Pract 2007; 76: 229-235.
18. Mazzone T, Meyer PM, Feinstein SΒL. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes. JAMA 2006; 296: 2572-2581.
19. Nissen SE, Nicholls SJ, Wolski K et al. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA 2008; 299: 1561-1573.
20. Haffner SM, Greenberg AS, Weston WM, Chen H, Williams K, Freed MI. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 2002; 106: 679-684.
21. Belfort R, Harrison SA, Brown K et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 2006; 355: 2297-2307.
22. Hanefeld M, Brunetti P, Schernthaner GH et al. One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes. Diabetes Care 2004; 27: 141-147.
23. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002; 347: 1557-1565.
24. Patterson C, Smith AE, Yarnell JWG, Rumley A, Lowe GDO, Ben-Shlomo Y. The associations of interleukin-6 (IL-6) and downstream inflammatory markers with risk of cardiovascular disease: The Caerphilly Study. Atherosclerosis 2010; 209: 551-557.
25. Hoekstra T, Geleijnse JM, Schouten EG, Kluft C. Plasminogen activator inhibitor-type 1: its plasma determinants and relation with cardiovascular risk. Thromb Haemost 2004; 91: 861-872.
26. Gerstein HC, Mann JF, Yi Q et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 2001; 286: 421-426.
27. Maeda H, Kubota A, Tanaka Y, Terauchi Y, Matsuba I. ASSET-K Study Group. The safety, efficacy and predictors for HbA1c reduction of sitagliptin in the treatment of Japanese type 2 diabetes. Diabetes Res Clin Pract 2012; 95: 20-22.
28. Dorkhan M, Frid A, Groop L. Differences in effects of insulin glargine or pioglitazone added to oral anti-diabetic therapy in patients with type 2 diabetes: what to add-insulin glargine or pioglitazone? Diabetes Res Clin Pract 2008; 82: 340-345.
29. Hartemann-Heurtier A, Halbron M, Golmard JL et al. Effects of bed-time insulin versus pioglitazone on abdominal fat accumulation, inflammation and gene expression in adipose tissue in patients with type 2 diabetes. Diabetes Res Clin Pract 2009; 86: 37-43.
30. Hermansen K, Kipnes M, Luo E, Fanurik D, Khatami H, Stein P. Sitagliptin Study 035 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabetes Obes Metab 2007; 9: 733-745.
31. Welch S, Gebhart SS, Bergman RN, Phillips LS. Minimal model analysis of intravenous glucose tolerance test-derived insulin sensitivity in diabetic subjects. J Clin Endocrinol Metab 1990; 71: 1508-1518.
32. Taniguchi A, Nakai Y, Fukushima M et al. Pathogenic factors responsible for glucose intolerance in patients with NIDDM. Diabetes 1992; 41: 1540-1546.
33. Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). Diabetes Care 2003; 26: 881-885.
34. Kikuchi K, Nezu U, Shirakawa J et al. Correlations of fasting and postprandial blood glucose increments to the overall diurnal hyperglycemic status in type 2 diabetic patients: variations with levels of HbA1c. Endocr J 2010; 57: 259-266.
35. Iwamoto Y, Tajima N, Kadowaki T et al. Efficacy and safety of sitagliptin monotherapy compared with voglibose in Japanese patients with type 2 diabetes: a randomized, double-blind trial. Diabetes Obes Metab 2010; 12: 613-622.
36. Rosaria MR, Marfella R, Barbieri M, Paolisso G. Reduction of oxidative stress and inflammation by blunting daily acute glucose fluctuations in patients with type 2 diabetes. Diabetes Care 2012; 35: 2076-2082.
37. Yki-Järvinen H. Thiazolidinediones. N Engl J Med 2004; 351: 106-1118.
38. Nakamura A, Osonoi T, Terauchi Y. Relationship between urinary sodium excretion and pioglitazone-induced edema. J Diabetes Invest 2010; 1: 208-211.